Biomarkers are an invaluable guide for optimising treatment in many diseases. Which biomarkers should we be utilising in colorectal cancer? When should we use them? And what impact do they have on treatment choices? The following e-learning course includes expert opinion on the latest answers to these important questions.
Should the site of colorectal cancer impact on treatment decisions? Are there meaningful differences in outcomes between patients depending on the site of their tumour? What should we do with the information we have available? Click through to learn more about this ongoing debate from our panel of experts.
Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer (mCRC)
Conventional first-line treatment continues until disease progression or intolerable toxicities. Today, the majority of patients discontinue due to side effects of chemotherapy. Recent studies have investigated the place of intermittent and continuous treatment regimens in patients with mCRC. Which is the best treatment approach? What impact do they have on potential outcomes? And which patients would best benefit from each approach? The following e-learning course includes expert opinion on the latest answers to these important questions.
While often thought of as a subgroup of colorectal cancer (CRC) patients, the elderly make up three out of every five cases. What does this mean for treatment, how should we assess their needs, and what should we do for those not fit for treatment? Click through for more discussion on the management of elderly and unfit CRC patients.